

"Express Mail" mailing label number EM564070285US

Date of Deposit November 2, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Olga M Franz
Printed Name

Olga M Franz
Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Accompanying Application

Applicants : Charles Jack Fisher et al.
For : METHODS FOR TREATING SEPSIS
Docket No. : X-12444A

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D. C. 20231

Sir:

Please amend the accompanying application as follows:

In the Specification

Please insert the following new first paragraph:

This case is a continuation of U.S. Serial No. 09/425,181 filed October 22, 1999, which claims the benefit of provisional application 60/105,239 filed October 22, 1998.

In the Claims

Please add the following new claims 16-32 and cancel Claims 1-15.

--16. A method of treating a human patient with sepsis which comprises, administering a continuous infusion of

5.0 $\mu\text{g/kg/hr}$ to 30 $\mu\text{g/kg/hr}$ of recombinant human activated protein C in combination with bacterial/permeability increasing (BPI) protein.

17. The method of Claim 16 wherein the BPI protein is recombinantly produced and is administered as a continuous infusion at about 50 $\mu\text{g/kg/hr}$ to about 300 $\mu\text{g/kg/hr}$.

18. The method of Claim 16 wherein the BPI protein is recombinantly produced and is administered as a continuous infusion at about 100 $\mu\text{g/kg/hr}$ to about 200 $\mu\text{g/kg/hr}$.

19. The method of any one of claims 16, 17, or 18 wherein the protein C plasma ranges in the human patient are from about 30 ng/ml to about 150 ng/ml.

20. The method of Claim 19 wherein the protein C plasma range in the human patient is 100 ng/ml.

21. The method of Claim 16 wherein about 0.1 mg/kg to about 10 mg/kg intravenous bolus of the BPI protein is administered followed by a continuous infusion of the BPI protein.

22. The method of Claim 19 wherein about 0.1 mg/kg to about 10 mg/kg intravenous bolus of BPI protein is administered followed by the continuous infusion.

23. The method of Claim 16 wherein the BPI protein is administered as an intermittent injection.

24. The method of Claim 16 wherein the human activated protein C infusion is administered for about 1 hour to about 240 hours.

25. The method of Claim 19 wherein the human activated protein C infusion is administered for about 1 hour to about 240 hours.

26. The method of Claim 17 wherein the BPI protein is administered for about 48 hours.

27. The method of Claim 18 wherein the BPI protein is administered for about 48 hours.

28. The method of Claim 24 wherein the BPI protein is administered for about 48 hours.

1099336560

29. The method of Claim 17 wherein the BPI protein is administered for 24 to 240 hours.

30. The method of Claim 18 wherein the BPI protein is administered for 24 to 240 hours.

31. The method of Claim 24 wherein the BPI protein is administered for 24 to 240 hours.

32. The method of any one of Claim 26, 27, 28, 29, 30 or 31 wherein the human activated protein C infusion and the BPI infusion are administered simultaneously.--

Remarks

This case is a continuation of U.S. Serial No. 09/425,181 filed October 22, 1999 (allowed). The Specification has been amended to update the priority information. New claims 16-32 are also being added via this amendment. Support for the claims may be found throughout the Specification, for example: Claim 16 (page 8, lines 21 and 22); Claims 17 and 18 (page 11, lines 5-8); Claims 19 and 20 (page 8, lines 33 and 34); Claims 21-23 (page 11, lines 8-14); Claims 24 and 25 (page 8, lines 8-11); Claims 26-28 (page 18, lines 2-4); Claims 29-31 (page 11, lines 8-12) and Claims 32 (page 10, lines 22-24 and page 18, lines 4-6). No new matter has been added by this amendment. Entry of the amendment is requested.

Applicants assert that the application is in condition for allowance and request that you contact the undersigned with any questions.

Respectfully submitted,

Brian P. Barrett

Brian P. Barrett
Attorney for Applicants
Registration No. 39,597
Phone: 317-276-7243

Eli Lilly and Company
Patent Division/BPB
Lilly Corporate Center
Indianapolis, Indiana 46285

November 1, 2001

[illegible]

New Claims after Preliminary Amendment

24. The method of Claim 16 wherein the human activated protein C infusion is administered for about 1 hour to about 240 hours.

32. The method of any one of Claim 26, 27, 28, 29, 30 or 31 wherein the human activated protein C infusion and the BPI infusion are administered simultaneously.

Figure 1 consists of 12 line drawings of a chick embryo at different stages of development, arranged vertically and labeled 1 through 12. The drawings show the progression from a single cell (1) to a fully formed chick with a beak and legs (12). The labels are as follows: 1. Fertilized egg; 2. Cleavage; 3. Blastoderm; 4. Gastrulation; 5. Somite formation; 6. Head development; 7. Limb bud formation; 8. Heart development; 9. Lung development; 10. Digestive tract development; 11. Circulatory system development; 12. Hatching.